Key Clinical Summary: 

• Design/Population: This single-center retrospective study evaluated pharmacist-led interventions in 11 patients with low-grade gliomas initiating vorasidenib therapy. Pharmacists conducted comprehensive medication reviews, drug-drug interaction assessments, and ongoing monitoring using a structured workflow.
• Key Outcomes: Clinically significant drug-drug interactions were identified and resolved in 82% of patients, with over half requiring medication changes prior to treatment initiation. Medication adherence was high, with 80% of patients achieving greater than 90% proportion of days covered.
• Clinical Relevance: Pharmacist-led management can help mitigate safety risks associated with vorasidenib, particularly due to its interaction profile. These findings support the development of structured medication therapy management models for patients receiving oral targeted therapies.

Results from a retrospective, single-center study suggest that pharmacist-led interventions play a critical role in optimizing medication management among patients with low-grade IDH2 mutation–positive gliomas receiving oral vorasidenib.

These results were presented at the Hematology/Oncology Pharmacy Association (HOPA) Annual Meeting in New Orleans, Louisiana, by Marie Noelle Bate Baiyee, PharmD, Tufts Medical Center in Boston, Massachusetts.

“Pharmacists play a critical role in initiating and monitoring patients receiving oral oncology medications, however, no established medication therapy management model exists for patients starting treatment with vorasidenib,” Baiyee and colleagues explained. 

In this study, researchers analyzed data from 11 patients scheduled to receive vorasidenib. Prior to treatment initiation, prescriptions were held in a multistep order transmission (MSOT) queue, allowing pharmacists to conduct comprehensive medication and chart reviews, including identification of potential drug-drug interactions, medication reconciliation, and benefits investigation. Providers were notified of clinically significant drug-drug interactions requiring therapy modification, and patients received counseling either in person or by telephone prior to treatment initiation.

Follow-up assessments were conducted every 30 days for the first 3 months and annually thereafter. Prescription refills were routed through the MSOT queue to allow pharmacist review of laboratory results, fill history, and new medications to ensure no new drug-drug interactions with vorasidenib. Researchers also monitored medication reconciliation, adverse events, and adherence using the proportion of days covered method and adapted questionnaires.

Clinically significant drug-drug interactions were identified and resolved in 82% of patients, with 55% requiring modification or discontinuation of at least 1 medication prior to initiating vorasidenib. A total of 21 medication therapy problems were identified, including 16 drug-drug interaction-related interventions, of which 9 were clinically significant. Additional interventions included adverse event management, contraceptive counseling, medication access support, and laboratory monitoring.

Medication adherence was high, with 80% of patients achieving a proportion of days covered greater than 90%. Pharmacist involvement enabled proactive identification and resolution of potential safety concerns throughout treatment.

“Close monitoring of patients with low-grade gliomas is vital to ensure safe, efficacious, and comprehensive care,” concluded Dr Baiyee and coauthors. “The findings from this study highlight the critical role of pharmacist-led interventions in optimizing medication therapy management in this complex patient population.” 

Source: 

Baiyee MNB, Hilliger M, Parlakkilic B, et al. Pharmacist-led management of vorasidenib in patients with isocitrate dehydrogenase mutation-positive gliomas. Presented at HOPA Annual. March 25-27, 2026. LB03.